1. Home
  2. RAND vs XLO Comparison

RAND vs XLO Comparison

Compare RAND & XLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rand Capital Corporation

RAND

Rand Capital Corporation

HOLD

Current Price

$11.25

Market Cap

34.6M

Sector

Finance

ML Signal

HOLD

XLO

Xilio Therapeutics Inc.

HOLD

Current Price

$8.48

Market Cap

39.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RAND
XLO
Founded
1969
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
34.6M
39.4M
IPO Year
1996
2021

Fundamental Metrics

Financial Performance
Metric
RAND
XLO
Price
$11.25
$8.48
Analyst Decision
Buy
Analyst Count
0
1
Target Price
N/A
$28.00
AVG Volume (30 Days)
4.5K
278.1K
Earning Date
03-05-2026
03-23-2026
Dividend Yield
9.80%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$43,766,000.00
Revenue This Year
N/A
$626.78
Revenue Next Year
N/A
$79.08
P/E Ratio
N/A
N/A
Revenue Growth
N/A
589.88
52 Week Low
$10.05
$0.46
52 Week High
$21.30
$8.64

Technical Indicators

Market Signals
Indicator
RAND
XLO
Relative Strength Index (RSI) 56.02 92.59
Support Level $10.31 $0.63
Resistance Level $12.50 N/A
Average True Range (ATR) 0.57 0.40
MACD 0.03 0.65
Stochastic Oscillator 82.15 98.48

Price Performance

Historical Comparison
RAND
XLO

About RAND Rand Capital Corporation

Rand Capital Corp is a closed-end, externally managed, non-diversified investment company. Its investment objective is to generate current income and, when possible, complement its current income with capital appreciation by focusing its debt and related equity investments in privately-held, lower middle market companies with committed and experienced managements in a broad variety of industries. It predominantly invests in higher-yielding debt instruments.

About XLO Xilio Therapeutics Inc.

Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies and immune cell engagers.

Share on Social Networks: